Abstract
BACKGROUND: It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm. METHODS: We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause. RESULTS: The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P = 0.40). Thus, there was no significant overall difference between the two treatments. In a time-varying analysis, the hazard ratio changed over time, slightly favoring warfarin over aspirin by the fourth year of follow-up, but this finding was only marginally significant (P = 0.046). Warfarin, as compared with aspirin, was associated with a significant reduction in the rate of ischemic stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P = 0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as compared with 0.87 in the aspirin group (P<0.001). The rates of intracerebral and intracranial hemorrhage did not differ significantly between the two treatment groups (0.27 events per 100 patient-years with warfarin and 0.22 with aspirin, P = 0.82). CONCLUSIONS: Among patients with reduced LVEF who were in sinus rhythm, there was no significant overall difference in the primary outcome between treatment with warfarin and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage. The choice between warfarin and aspirin should be individualized. (Funded by the National Institute of Neurological Disorders and Stroke; WARCEF ClinicalTrials.gov number, NCT00041938.)
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1859-1869 |
| Number of pages | 11 |
| Journal | New England Journal of Medicine |
| Volume | 366 |
| Issue number | 20 |
| DOIs | |
| State | Published - May 17 2012 |
| Externally published | Yes |
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Warfarin and aspirin in patients with heart failure and sinus rhythm'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: New England Journal of Medicine, Vol. 366, No. 20, 17.05.2012, p. 1859-1869.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Warfarin and aspirin in patients with heart failure and sinus rhythm
AU - Homma, Shunichi
AU - Thompson, John L.P.
AU - Pullicino, Patrick M.
AU - Levin, Bruce
AU - Freudenberger, Ronald S.
AU - Teerlink, John R.
AU - Ammon, Susan E.
AU - Graham, Susan
AU - Sacco, Ralph L.
AU - Mann, Douglas L.
AU - Mohr, J. P.
AU - Massie, Barry M.
AU - Labovitz, Arthur J.
AU - Anker, Stefan D.
AU - Lok, Dirk J.
AU - Ponikowski, Piotr
AU - Estol, Conrado J.
AU - Lip, Gregory Y.H.
AU - Di Tullio, Marco R.
AU - Sanford, Alexandra R.
AU - Mejia, Vilma
AU - Gabriel, Andre P.
AU - Del Valle, Mirna L.
AU - Buchsbaum, Richard
AU - Moy, C.
AU - Gilbert, P.
AU - Gutmann, L.
AU - Marler, J.
AU - Borden, S.
AU - Peña, E.
AU - Harris, C.
AU - Khadouri, R.
AU - Gohs, D.
AU - Brown, M.
AU - Berry, G.
AU - Disantis, D.
AU - Scullin, M.
AU - Smith, P.
AU - Kohsaka, S.
AU - Watson, W.
AU - Guillory, L.
AU - Levy, G.
AU - Tea, K.
AU - Grier, J.
AU - Swydan, L.
AU - O'Hare, B.
AU - Prodhan, R.
AU - Arbing, R.
AU - Flanagan, E.
AU - Duverger, E.
AU - Peljto, A.
AU - Lo, W.
AU - Tierney, A.
AU - Henriquez, A.
AU - Keen, J.
AU - del Zoppo, G. J.
AU - Albers, G. W.
AU - Eliasziw, M.
AU - Hinchey, J. A.
AU - Johnston, K. C.
AU - Lowe, A. M.
AU - Piña, I. L.
AU - Swain, J. A.
AU - Slomiak, S.
AU - Cape, L.
AU - Barnett, H. J.
AU - Bruno, A.
AU - Easton, J. D.
AU - Levine, S.
AU - Sahlas, D.
AU - Bleyer, F.
AU - Carson, P.
AU - Ellis, A.
AU - Miller, A.
AU - Palmeri, S. T.
AU - Bierig, M.
AU - Liu, R.
AU - Donato, C.
AU - Hart, R.
AU - McKay, C.
AU - Wilson, L.
AU - Frey, E.
AU - Hayward, K.
AU - Stein-Beal, P.
AU - Konczarek, L.
AU - Diek, M.
AU - Rohwedder, M.
AU - Bohdanowicz-Zazula, M.
AU - Peerenboom-Fey, C. F.
AU - Vissiennon, M.
AU - Rex, G.
AU - Varga, M.
AU - Kovtun, O.
AU - Orlyk, V.
AU - Arenberger, P.
AU - Jaros, J.
AU - Ruiz, A.
AU - Zimmermann, M.
AU - Ellenberg, A.
AU - Minagar, A.
AU - Kelley, R.
AU - McGee, J.
AU - Jinkins, P.
AU - Bezucha, S.
AU - Hart, V.
AU - Bonora, M.
AU - Sawyer, R.
AU - Ammerman, K.
AU - Ramappa, P.
AU - Berchou, V.
AU - Jones, E.
AU - Olgren, E.
AU - Hattler, B.
AU - Anderson, C.
AU - Watson, B.
AU - Wolf, D.
AU - Kosits, J.
AU - Casazza, L.
AU - Yip, D.
AU - Meschia, J.
AU - McPhail, A.
AU - Greenan, K.
AU - Rothbart, R.
AU - Love, J.
AU - Schrader, T.
AU - Garman, V.
AU - Stoddard, M.
AU - Remmel, K.
AU - Longaker, R.
AU - Gerula, C.
AU - Klapholz, M.
AU - Kirmani, J.
AU - Mattessich, R.
AU - Rodriguez, C.
AU - Graettinger, W.
AU - Baker, A.
AU - Valencia, A.
AU - Kosolcharoen, P.
AU - Williams, L.
AU - Sorrell, V.
AU - Coull, B.
AU - Bruck, D.
AU - Ofili, E.
AU - Frankel, M.
AU - Jackson, P.
AU - Nanna, M.
AU - Sparr, S.
AU - Almeida, W.
AU - Libman, R.
AU - Stephens, B.
AU - DeMers, C.
AU - Giles, T.
AU - Roffidal, L.
AU - Barratt, D.
AU - Liston, M.
AU - Lindsey, C.
AU - Giron, L.
AU - Felton, W.
AU - Joseph, L.
AU - Lee, M.
AU - Bisognano, J.
AU - Benesch, C.
AU - Caufield, L.
AU - Nishime, E.
AU - Moussavian, M.
AU - Polland, E.
AU - Fischer, L.
AU - Peterson, K.
AU - McGinnis, B.
AU - Tilem, M.
AU - Allam, G.
AU - Beebe, J.
AU - Chang, P.
AU - Sen, S.
AU - Schuler, C.
AU - Arcement, L.
AU - Charlet, M.
AU - Falgout, E.
AU - Malkowski, M.
AU - Dugan, T.
AU - Hobbs-Williams, J.
AU - Warner, A.
AU - Panizzon, K.
AU - Johnson, J.
AU - Dissin, J.
AU - Karia, D.
AU - Molakala, N.
AU - Dandapani, B.
AU - Vicari, R.
AU - Anthony, E.
AU - Katzan, I.
AU - Hobbs, R.
AU - Richmond, A.
AU - Hughes, R.
AU - Baker, W.
AU - Applegate, M.
AU - Drachman, B.
AU - Khella, S.
AU - Donovan, S.
AU - Slim, A.
AU - Pearce Moore, D.
AU - Darrow, B.
AU - Travis, A.
AU - Mercando, A.
AU - Pellegrino, R.
AU - Jarmukli, N.
AU - Ochalek, T.
AU - Janosik, D.
AU - Dizes, J.
AU - Pettigrew, L. C.
AU - Taylor, D.
AU - Hanna, J.
AU - Bailey, S.
AU - Berkowitz, R.
AU - Mathus, S.
AU - Virkud, V.
AU - Shaw, S.
AU - Nabhan, S.
AU - Wirkowski, E.
AU - George, B.
AU - Smith, E.
AU - Locke, S.
AU - Landau, C.
AU - Ferguson, D.
AU - Anderson, H. V.
AU - Westbrook, L.
AU - Apelian, M.
AU - Khoury, S.
AU - Leppo, J.
AU - Bator, T.
AU - Thadani, U.
AU - Turner, J.
AU - Goldman, S.
AU - Daugherty, S.
AU - Adler, A.
AU - Rennie, T.
AU - Chupka, D.
AU - Katz, R.
AU - Witkin, L.
AU - Burgin, W.
AU - Weber, C.
AU - Boehmer, J.
AU - Frey, P.
AU - Wilson, M.
AU - Tworek, H.
AU - Mallis, G.
AU - Mauceri, D.
AU - Schneider, R.
AU - Schneider, W.
AU - Ortiz, G.
AU - Lichtenberger, M.
AU - Hott, B.
AU - Patrick, D.
AU - Dunlap, S.
AU - Kim, S. J.
AU - Pezzella, S.
AU - Aubin, D.
AU - Nikolaidis, L.
AU - Wong, J.
AU - Leifer, D.
AU - Rossi, M.
AU - Torre, G.
AU - Arredondo, J.
AU - Lynch, J.
AU - Metcalf, A.
AU - Gonzalez, J.
AU - Donley, B.
AU - Cappola, T.
AU - Craig, K.
AU - Bozkurt, B.
AU - Bolos, M.
AU - Noonan, T.
AU - Alteri, C.
AU - Kowalczyk, L.
AU - Cwynar, A.
AU - Drazek, D.
AU - Biegus, J.
AU - Szelemej, R.
AU - Jurczok, M.
AU - Serafin, R.
AU - Jurczyk, A.
AU - Ogorek, M.
AU - Kopcik, D.
AU - Metzkier-Wyrwa, B.
AU - Szczepanska, A.
AU - Dluzniewski, M.
AU - Wicha, W.
AU - Kuch, M.
AU - Kuc, K.
AU - Piotrowski, R.
AU - Lesniak, O.
AU - Krauze-Wielicka, M.
AU - Herman, J.
AU - Nowakowska, S.
AU - Pasierski, T.
AU - Kozlowski, B.
AU - Wolkowska, K.
AU - Juszczak, A.
AU - Michalska, J.
AU - Jedlinski, I.
AU - Miekus, P.
AU - Konarzewski, M.
AU - Berkowski, P.
AU - Jacek, N.
AU - Kalarus, Z.
AU - Duszanska, A.
AU - Tarchalski, J.
AU - Czaja, P.
AU - Gaciong, Z.
AU - Gora, J.
AU - Kleinrok, A.
AU - Prokop-Lewicka, G.
AU - Haddad, H.
AU - Davies, R.
AU - Sitwell, L.
AU - Donaldson, J.
AU - To, T.
AU - Yufe, R.
AU - Donelly, B.
AU - Huynh, T.
AU - Cote, R.
AU - St Jacques, B.
AU - Borts, D.
AU - Tullio, G.
AU - Sindilar, A. M.
AU - Winder, T.
AU - Janzen, E.
AU - Walker, C.
AU - Moe, G.
AU - Bayer, N.
AU - Konig, A.
AU - Arnold, M.
AU - Spence, D.
AU - Smith, J.
AU - Bessoudo, R.
AU - Bailey, P.
AU - McNulty, A.
AU - Nawaz, S.
AU - Dewar, C.
AU - Rajda, M.
AU - MacFarlane, M.
AU - Minuk, J.
AU - Schanz, C.
AU - Penn, A.
AU - Atkins, L.
AU - Ducharme, A.
AU - Brown, H.
AU - Zieroth, S.
AU - Muñoz, A.
AU - ten Holter, J. B.
AU - Huls, C.
AU - Bruggink-Andre, P.
AU - van Bujisen-Nutters, A.
AU - Daniels, M.
AU - Coppes, A.
AU - van Zagten, M.
AU - Elzebroek, N.
AU - Hamroui, K.
AU - de Kort, P.
AU - Vuijsters, J.
AU - Holwerda, N.
AU - Hermans, W.
AU - van der Loo, R.
AU - Wajon, E.
AU - Hageman, G.
AU - v Buchem-Damming, G.
AU - Ronner, E.
AU - Wissenburg-van Lieshout, A.
AU - Niekus, H.
AU - van Hessen, M. W.
AU - Verheul, G. A.
AU - Linssen, G.
AU - te Pas, L.
AU - Plomp, J.
AU - de Milliano, P. A.
AU - Breedveld, R.
AU - Bos, M. J.
AU - Houra, M.
AU - Beran, D.
AU - Lebedova, R.
AU - Carda, J.
AU - Bednarova, E.
AU - Vosmerova, J.
AU - Marcinek, G.
AU - Drasnar, T.
AU - Najmanova, O.
AU - Dunaj, M.
AU - Pechackova, E.
AU - Kuchar, M.
AU - Jansky, P.
AU - Simon, J.
AU - Dvorakova, H.
AU - Gregor, P.
AU - Maruskova, M.
AU - Svoboda, L.
AU - Lorenc, Z.
AU - Kralicek, P.
AU - Pollak, L.
AU - Krobot, Z.
AU - Krobot, M.
AU - Spinar, J.
AU - Nemec, M.
AU - Spinarova, L.
AU - Kuba, R.
AU - Padour, F.
AU - Padourova, I.
AU - Padour, M.
AU - Michalova, M.
AU - Golan, L.
AU - Hajkova, M.
AU - Povolny, J.
AU - Krizova, L.
AU - Horak, D.
AU - Kucera, P.
AU - Malek, I.
AU - Krizova, B.
AU - Svoboda, J.
AU - Ferkl, R.
AU - Regos, L.
AU - Csuros, L.
AU - Lovasz, O.
AU - Kiss, G.
AU - Timar, S.
AU - Torok, N.
AU - Hajnalne, A.
AU - Palossy, B.
AU - Nagy, A.
AU - Fulop, P.
AU - Jakab, G.
AU - Ronaszeki, A.
AU - Bodi, M.
AU - Satori, M.
AU - Edes, I.
AU - Varga, I.
AU - Kovacs, A.
AU - Berente, L.
AU - Péterfai, E.
AU - Pauer, R.
AU - Toth, K.
AU - Nagy, E.
AU - Benczur, B.
AU - Karsay, K.
AU - Végh, T.
AU - Nagy, R.
AU - Karpati, P.
AU - Davidovits, Z.
AU - Borbola, J.
AU - Vanyi, J.
AU - Oze, B.
AU - Bujdoso, A.
AU - Kosa, I.
AU - Baliko, L.
AU - Natour, M.
AU - Morgil, M.
AU - Hartmann, E.
AU - Morgil, H.
AU - Winkler, R.
AU - Gass, S.
AU - Baumann, S.
AU - Jeserich, M.
AU - Rodl, J.
AU - Dzaiy, M.
AU - Turhan, G.
AU - Wolf, K.
AU - Genth-Zotz, S.
AU - Siebert, T.
AU - Jakobs, C.
AU - Kiorwantsi, M.
AU - Pieske, B.
AU - Wachter, R.
AU - Schoenauer, M.
AU - Voigt, S.
AU - Schunkert, H.
AU - Boguschewski, A.
AU - Resch, M.
AU - Wensel, R.
AU - Schumann, V.
AU - Heidrich, P.
AU - Girina, O.
AU - Prokopovych, Y.
AU - Lebedynska, M.
AU - Sorokina, I.
AU - Karpenko, O.
AU - Brodi, N.
AU - Klochkov, S.
AU - Voronkov, L.
AU - Besaga, Y.
AU - Novikova, O.
AU - Amosova, K.
AU - Yaremenko, O.
AU - Balaban, K.
AU - Kovalenko, V.
AU - Polenova, N.
AU - Sakharchuk, I.
AU - Ogorodnichuk, A.
AU - Rudenko, L.
AU - Tutov, Y.
AU - Parkhomenko, A.
AU - Kozhukhov, S.
AU - Yakimenko, E.
AU - Kolomiets, S.
AU - Yurlov, V.
AU - Tikhonova, S.
AU - Elizalde, A.
AU - Mangariello, B.
AU - Zaidman, C.
AU - Guerlloy, F.
AU - Gitelman, P.
AU - Crotto, K.
AU - Sassone, S.
AU - Aiub, J.
AU - Novoa, F.
AU - Lopez Santi, R.
AU - Romia, P.
AU - Montaña, O.
AU - Malchik, D.
AU - Sokn, F.
AU - Schygiel, P.
AU - Porcile, R.
AU - Soria Tito, F.
AU - Thierer, J.
AU - Avellana, P.
AU - Rapallo, C.
AU - Calderon, M.
AU - MacFadyen, R.
AU - Haynes, R.
AU - Partridge, J.
AU - Kokles, M.
AU - Mehešová, S.
AU - Zachar, A.
AU - Hranai, M.
AU - Varadyova, T.
AU - Göbö, T.
AU - Litvinova, J.
AU - Loviska, P.
N1 - Funding Information: Acknowledgements. The authors gratefully acknowledgement the support of the National Natural Science Foundation of China (11961043, 11561043), and STU Scientific Research Initiation Grant.
PY - 2012/5/17
Y1 - 2012/5/17
N2 - BACKGROUND: It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm. METHODS: We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause. RESULTS: The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P = 0.40). Thus, there was no significant overall difference between the two treatments. In a time-varying analysis, the hazard ratio changed over time, slightly favoring warfarin over aspirin by the fourth year of follow-up, but this finding was only marginally significant (P = 0.046). Warfarin, as compared with aspirin, was associated with a significant reduction in the rate of ischemic stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P = 0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as compared with 0.87 in the aspirin group (P<0.001). The rates of intracerebral and intracranial hemorrhage did not differ significantly between the two treatment groups (0.27 events per 100 patient-years with warfarin and 0.22 with aspirin, P = 0.82). CONCLUSIONS: Among patients with reduced LVEF who were in sinus rhythm, there was no significant overall difference in the primary outcome between treatment with warfarin and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage. The choice between warfarin and aspirin should be individualized. (Funded by the National Institute of Neurological Disorders and Stroke; WARCEF ClinicalTrials.gov number, NCT00041938.)
AB - BACKGROUND: It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm. METHODS: We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause. RESULTS: The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P = 0.40). Thus, there was no significant overall difference between the two treatments. In a time-varying analysis, the hazard ratio changed over time, slightly favoring warfarin over aspirin by the fourth year of follow-up, but this finding was only marginally significant (P = 0.046). Warfarin, as compared with aspirin, was associated with a significant reduction in the rate of ischemic stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P = 0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as compared with 0.87 in the aspirin group (P<0.001). The rates of intracerebral and intracranial hemorrhage did not differ significantly between the two treatment groups (0.27 events per 100 patient-years with warfarin and 0.22 with aspirin, P = 0.82). CONCLUSIONS: Among patients with reduced LVEF who were in sinus rhythm, there was no significant overall difference in the primary outcome between treatment with warfarin and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage. The choice between warfarin and aspirin should be individualized. (Funded by the National Institute of Neurological Disorders and Stroke; WARCEF ClinicalTrials.gov number, NCT00041938.)
UR - http://www.scopus.com/inward/record.url?scp=84861037910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861037910&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1202299
DO - 10.1056/NEJMoa1202299
M3 - Article
C2 - 22551105
AN - SCOPUS:84861037910
SN - 0028-4793
VL - 366
SP - 1859
EP - 1869
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 20
ER -